Us­ing AI to se­quence fun­gi genomes for can­cer treat­ments, Hexa­gon Bio nets $47M in Se­ries A

A Stan­ford spin­out ex­plor­ing how fun­gi can be se­quenced to dis­cov­er new med­i­cines in on­col­o­gy and in­fec­tious dis­eases now has sig­nif­i­cant­ly more cash to do so.

Ear­ly Tues­day morn­ing, Hexa­gon Bio an­nounced the clos­ing of their Se­ries A fi­nanc­ing, pulling in $47 mil­lion from a group of in­vestors led by The Col­umn Group. The round, which al­so saw par­tic­i­pa­tion from 8VC and Two Sig­ma Ven­tures, will go to­ward cre­at­ing a pro­pri­etary ge­nomics data­base as well as build­ing out a drug dis­cov­ery team to de­vel­op the new com­pounds. Hexa­gon brought on Tod Smeal as its new CSO af­ter he served in the same po­si­tion at Lil­ly Re­search Labs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER